Access and Delivery of Essential Medicines

2006 Archive

A .mov player such as Quicktime is required to watch videos after 2009.

Realplayer is required to watch videos older than 2009. Free Realplayer 11 is located at: and Realplayer 10.5 is located at

Introductory Talk:

Is There Any Hope for Tackling the World’s Most Neglected Diseases?

Gavin Yamey, MD MRCP, Senior Editor PLoS Medicine
Patrick Brown, MD PhD, Co-Founder PLoS
Feb 2006
Gavin Yamey defines what Neglected Tropical Disease are and highlights their impact on global health. He explains why these diseases are neglected and what we can do about it. Finally, PLoS Neglected Tropical Diseases is revealed.
Watch Video



Drugs for the Developing World

Stephen Maurer, JD, Acting Director of the Goldman School Project on Information Technology and Homeland Security; University of California, Berkeley
Feb 2006
Watch Video


Finding Cures for Tropical Disease: Open Sources and the Tropical Disease Initiative

Marc A. Marti-Renom, PhD
Feb 2006
Marc Marti-Renom discusses approaches to funding research and treatments for tropical diseases.  While these diseases receive less publicity than the Big 3 ( HIV, Malaria, TB - not crude touch, pain, and temperature), neglected tropical diseases effect the poor just as much but have treatment and prevention strategies that can be delivered for less than $1/person/year.
Watch Video


Vaccine production in developing nations; lessons from history

John H. Barton, JD, Emeritus Co-director, Stanford Program in Law, Science & Technology
Mar 2006
John Barton has been instrumental in working with the NIH on reform efforts involving the structure of the pharmaceutical industry, the transfer of vaccine technology to the developing world, and international decision-making in the medical arena. Dr. Barton has recently published an article in the Journal of the American Medical Association on the pharmaceutical development process, and is co-author of the product development priorities chapter in the forthcoming book Disease Control Priorities in Developing Countries. He has participated extensively in discussions regarding drug access for developing nations. He is also interested in the marketing structure of the pharmaceutical industry and the impact of vaccine regulation on the structure of the international vaccine industry.
Watch Video


Footer Links: